Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced breast cancer (PALOMA-1; TRIO-18)

Finn, Richard S. and Crown, John and Lang, Istvan and Boer, Katalin and Bondarenko, Igor and Kulyk, Sergey O. and Ettl, Johannes and Patel, Ravindranath and Pinter, Tamas and Schmidt, Marcus and Shparyk, Yaroslav V. and Thummala, Anu and Voytko, Nataliya L. and Fowst, Camilla and Huang, Xin and Kim, Sindy and Slamon, Dennis J. (2017) Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced breast cancer (PALOMA-1; TRIO-18). Journal of Clinical Oncology, 35 (15). p. 1001. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)

Text Overall survival results from the randomized phase II study of palbociclib.docx Download (18kB)

Abstract

Background: Preclinical data identified a synergistic role for P and hormone blockade in blocking growth of ER+ breast cancer (BC) cell lines. PALOMA-1 was an open-label phase II trial comparing progression-free survival (PFS) in patients (pts) with advanced ER+/HER2–BC treated with P+ L or L alone. Median PFS increased with addition of P to L to 20.2 mos (vs 10.2 mos with L alone; HR= 0.488), with an acceptable safety profile, leading to accelerated approval by the US FDA. These results were confirmed in the phase 3 ...

Item Type:	Article
Subjects:	Oncology
Divisions:	Departments > Department of Oncology and Medical Radiology
Depositing User:	Елена Шрамко
Date Deposited:	07 Sep 2017 11:18
Last Modified:	07 Sep 2017 11:18
URI:	http://repo.dma.dp.ua/id/eprint/1923

Actions (login required)

View Item